A Randomized, Open-label, Multiple-dose, Two-period, Crossover, Study to Investigate the Pharmacokinetic Profile of 2 Formulations of JKB-122 in Healthy Male Subjects
Latest Information Update: 07 Jul 2022
At a glance
- Drugs JKB 122 (Primary)
- Indications Autoimmune hepatitis
- Focus Pharmacokinetics
- Sponsors TaiwanJ Pharmaceuticals
Most Recent Events
- 13 Jul 2020 Planned End Date changed from 1 Aug 2020 to 1 Dec 2020.
- 13 Jul 2020 Planned primary completion date changed from 1 Jul 2020 to 1 Dec 2020.
- 13 Jul 2020 Planned initiation date changed from 1 Apr 2020 to 1 Aug 2020.